ITMI20012160A1 - Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test - Google Patents
Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test Download PDFInfo
- Publication number
- ITMI20012160A1 ITMI20012160A1 IT2001MI002160A ITMI20012160A ITMI20012160A1 IT MI20012160 A1 ITMI20012160 A1 IT MI20012160A1 IT 2001MI002160 A IT2001MI002160 A IT 2001MI002160A IT MI20012160 A ITMI20012160 A IT MI20012160A IT MI20012160 A1 ITMI20012160 A1 IT MI20012160A1
- Authority
- IT
- Italy
- Prior art keywords
- sequence
- phosphoprotein
- sample
- module
- strip
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 10
- 241000701022 Cytomegalovirus Species 0.000 title claims abstract description 8
- 238000012360 testing method Methods 0.000 title claims description 15
- 238000012512 characterization method Methods 0.000 title abstract description 5
- 230000000890 antigenic effect Effects 0.000 title description 5
- 238000012790 confirmation Methods 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 238000002965 ELISA Methods 0.000 claims abstract description 9
- 239000004793 Polystyrene Substances 0.000 claims abstract description 3
- 229920002223 polystyrene Polymers 0.000 claims abstract description 3
- 102000007982 Phosphoproteins Human genes 0.000 claims description 18
- 108010089430 Phosphoproteins Proteins 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 12
- 229920000936 Agarose Polymers 0.000 claims description 10
- 101710120037 Toxin CcdB Proteins 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 229940072221 immunoglobulins Drugs 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 230000007420 reactivation Effects 0.000 claims description 3
- 230000009257 reactivity Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000013642 negative control Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims 2
- 241001649081 Dina Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000013060 biological fluid Substances 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 108010008038 Synthetic Vaccines Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108700010903 cytomegalovirus proteins Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI002160A ITMI20012160A1 (it) | 2001-10-18 | 2001-10-18 | Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test |
| AT02425624T ATE354093T1 (de) | 2001-10-18 | 2002-10-14 | Elisa bestätigungstest für frühe primarinfektion durch zytomegaloviren |
| DE60218098T DE60218098D1 (de) | 2001-10-18 | 2002-10-14 | Elisa Bestätigungstest für frühe Primarinfektion durch Zytomegaloviren |
| EP02425624A EP1304574B1 (de) | 2001-10-18 | 2002-10-14 | Elisa Bestätigungstest für frühe Primarinfektion durch Zytomegaloviren |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI002160A ITMI20012160A1 (it) | 2001-10-18 | 2001-10-18 | Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20012160A1 true ITMI20012160A1 (it) | 2003-04-18 |
Family
ID=11448517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2001MI002160A ITMI20012160A1 (it) | 2001-10-18 | 2001-10-18 | Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1304574B1 (de) |
| AT (1) | ATE354093T1 (de) |
| DE (1) | DE60218098D1 (de) |
| IT (1) | ITMI20012160A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0418084A (pt) * | 2003-12-23 | 2007-04-17 | Maharashtra Hybrid Seeds Compa | método para a preparação de suporte sólido pronto-para-usar para ensaio imunoabsorvente ligado a enzima (elisa) rápido |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| PE20141432A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| KR101805927B1 (ko) * | 2008-12-25 | 2017-12-06 | 유니바사루 바이오 리사치 가부시키가이샤 | 검체의 전처리 방법, 및 생체 관련 물질의 측정 방법 |
| US10309964B2 (en) | 2015-02-09 | 2019-06-04 | Xiamen University | Method for assessing risk of human cytomegalovirus active infection in body and related kit |
| CN105974111B (zh) * | 2016-07-20 | 2019-07-09 | 国家纳米科学中心 | 一种类风湿因子(IgM型)及其他抗原特异性IgM抗体联合检测的方法 |
| CN107656057A (zh) * | 2017-09-06 | 2018-02-02 | 中国农业科学院兰州兽医研究所 | 一种用于检测布鲁氏杆菌病IgM抗体的ELISA试剂盒及其应用 |
| CN109358192B (zh) * | 2018-02-08 | 2020-05-12 | 中国科学院上海药物研究所 | 一种去除抗药抗体检测样品中游离药物的装置和方法、该装置的制备方法及应用 |
| WO2020061135A1 (en) * | 2018-09-18 | 2020-03-26 | Siemens Healthcare Diagnostics Inc. | Methods and reagents for zika virus immunoassays |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE225942T1 (de) * | 1996-07-12 | 2002-10-15 | Organon Teknika Bv | Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv) |
-
2001
- 2001-10-18 IT IT2001MI002160A patent/ITMI20012160A1/it unknown
-
2002
- 2002-10-14 EP EP02425624A patent/EP1304574B1/de not_active Expired - Lifetime
- 2002-10-14 AT AT02425624T patent/ATE354093T1/de not_active IP Right Cessation
- 2002-10-14 DE DE60218098T patent/DE60218098D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60218098D1 (de) | 2007-03-29 |
| EP1304574A3 (de) | 2003-12-17 |
| EP1304574B1 (de) | 2007-02-14 |
| ATE354093T1 (de) | 2007-03-15 |
| EP1304574A2 (de) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112229994B (zh) | 一种基于磁微粒化学发光的新型冠状病毒抗体检测试剂盒 | |
| US8114408B2 (en) | Peptide fragments reacting specifically with antibodies against highly pathogenic newcastle disease virus and uses thereof | |
| Katz et al. | ELISA for detection of group-common and virus-specific antibodies in human and simian sera induced by herpes simplex and related simian viruses | |
| CN112964884B (zh) | 一种诊断标志物及其在covid-19诊断及冠状病毒既往感染检测中的应用 | |
| ITMI20012160A1 (it) | Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test | |
| JPH0767700A (ja) | 合成ペプチドを使用するｈｔｌｖ試験 | |
| EP1328811B1 (de) | Hcv mosaik antigen zusammensetzung | |
| KR100624517B1 (ko) | 인간 사이토메갈로바이러스 검출용 펩티드 시약 | |
| CN113024640A (zh) | 一种基于新冠病毒rbd与ace2受体结合结构域筛选的表位肽抗原检测中和抗体试剂盒 | |
| WO2006043614A1 (ja) | メンブランエンザイムイムノアッセイ法 | |
| US20210347856A1 (en) | Monoclonal antibody 14f5f6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2 | |
| CN101644709A (zh) | 快速检测病毒中和抗体的方法和试剂盒 | |
| WO1991013360A1 (en) | NEW HIV p24 PEPTIDES, DIAGNOSTIC ANTIGENS AND DISCRIMINATIVE IMMUNOASSAY METHOD | |
| Vlock et al. | Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration | |
| JP5592277B2 (ja) | エプスタイン−バーウイルス（ｅｂｖ）再活性化のインビトロ診断のためのｚｅｂｒａタンパク質由来合成ペプチドの使用 | |
| Cranage et al. | The use of monoclonal antibodies in (reverse) passive haemagglutination tests for herpes simplex virus antigens and antibodies | |
| CN109799342A (zh) | 一种o型口蹄疫病毒抗体竞争elisa检测试剂盒 | |
| CN213398575U (zh) | 新型冠状病毒IgM/IgG快速检测的试纸条和试剂盒 | |
| JPS60155974A (ja) | 分子クロ−ンされた診断用産物 | |
| Marennikova et al. | ELISA—a simple test for detecting and differentiating antibodies to closely related orthopoxviruses | |
| US12098185B2 (en) | Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2 | |
| Gerna et al. | Rapid detection of human cytomegalovirus and herpesvirus hominis IgM antibody by the immunoperoxidase technique | |
| ES2674672T3 (es) | Péptidos de interferencia y procedimiento de detección de microorganismos | |
| US9915662B2 (en) | Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients | |
| And et al. | Humoral immune response to virions and dense bodies of human cytomegalovirus determined by enzyme immunofluorescence assay |